

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
21 July 2005 (21.07.2005)

PCT

(10) International Publication Number  
**WO 2005/065688 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/501**,  
A61P 7/02, C07D 403/12, 403/14

(74) Agent: **ASTRAZENECA**; Global Intellectual Property,  
S-151 85 Södertälje (SE).

(21) International Application Number:  
PCT/SE2005/000011

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 5 January 2005 (05.01.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0400014-7 8 January 2004 (08.01.2004) SE

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): **BRATT, Emma** [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). **CHEN, Yantao** [CN/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). **GRANBERG, Kenneth** [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). **NILSSON, Ingemar** [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE).

Published:

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: NEW DERIVATIVES OF 6-4[4-[1H-INDOLE-2-SULPHONYL)-PIPERAZIN-1-CARBONYL-PHENYL]]PYRADIZIN-3-ONE



(57) Abstract: The invention relates to heterocyclic derivatives of formula (I), wherein R<sup>2</sup> is amino, a group OR<sup>4</sup> or a group -YR<sup>5</sup> where R<sup>4</sup> is hydrogen or C<sub>1-4</sub>alkyl, Y is C<sub>1-4</sub>alkylene, R<sup>5</sup> is hydrogen, halo, hydroxy, C<sub>1-2</sub>alkoxy, C<sub>1-2</sub>alkoxyC<sub>1-2</sub>alkoxyC<sub>1-4</sub>, or a group NR<sup>7</sup>R<sup>8</sup> where R<sup>7</sup> and R<sup>8</sup> are independently selected from hydrogen, C<sub>1-2</sub>alkyl, hydroxyC<sub>1-2</sub>alkyl or alkoxyC<sub>1-2</sub>alkyl, or R<sup>7</sup> and R<sup>8</sup> together with the nitrogen atom to which they are attached form a saturated 5-6-membered heterocyclic ring which optionally contains an additional heteroatom; n is one or two and each R<sup>1</sup> is independently selected from halo, haloC<sub>1-2</sub>alkyl, hydroxy, oxo, amino, C<sub>1-2</sub>alkylamino or di-C<sub>1-2</sub>dialkylamino; or a pharmaceutically acceptable salt thereof. These compounds possess antithrombotic and anticoagulant properties and are accordingly useful in methods of treatment of humans or animals. The invention also relates to processes for the preparation of the heterocyclic derivatives, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an antithrombotic or anticoagulant effect.

WO 2005/065688 A1